This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Karpati, G. Articles by Holland, P. Search for Related Content PubMed PubMed Citation Articles by Karpati, G. Articles by Holland, P.

American Journal of Pathology, Vol 135, 27-32, Copyright © 1989 by American Society for Investigative Pathology

REGULAR ARTICLES

Dystrophin is expressed in mdx skeletal muscle fibers after normal myoblast implantation

G Karpati, Y Pouliot, E Zubrzycka-Gaarn, S Carpenter, PN Ray, RG Worton and P Holland
Neuromuscular Research Group, Montreal Neurological Institute, McGill University, Quebec, Canada.

In mdx mice, the dystrophin gene of the X chromosome is defective and, as a result, immunoreactive dystrophin is undetectable in all muscle fibers of all animals of this highly inbred strain. This study showed that implantation of suspensions of clonal cultures of normal human myoblasts into different regions of quadriceps muscles of 6-to-10-day- old mdx mice or 60-day-old mdx mice (whose muscles have been crushed 4 days before implantation) results in the appearance of scattered fiber segments containing microscopically demonstrable immunoreactive dystrophin. In the animals that received the normal myoblast implantation in the prenecrotic stage of the disease (6 to 10 days of age), the dystrophin-positive fiber segments (demonstrated at ages 35, 45, and 60 days) escaped necrosis. This was determined by the absence of the characteristic chains of central nuclei, a reliable marker of prior necrosis in mdx muscle fibers. By heavy labeling of the nuclear DNA of the transplantable human myoblasts with H3-thymidine during culturing, and by sequential performance of an immunocytochemical staining for dystrophin and autoradiography on the same sections, some dystrophin-positive fiber segments were shown to contain radiolabeled myonuclei. It was concluded that nondystrophic myoblasts fused with host muscle fibers to form mosaic muscle fibers in which the normal dystrophin gene of the implanted myoblasts was expressed. This approach may be employed for the mitigation of the deleterious consequences of a gene defect in recessively inherited human muscle diseases such as Duchenne dystrophy.

This article has been cited by other articles:

				E. S. Luth, S. J. Jun, M. K. Wessen, K. Liadaki, E. Gussoni, and L. M. Kunkel Bone marrow side population cells are enriched for progenitors capable of myogenic differentiation J. Cell Sci., May 1, 2008; 121(9): 1426 - 1434. [Abstract] [Full Text] [PDF]

				S. H.A. Wong, K. N. Lowes, I. Bertoncello, A. F. Quigley, P. J. Simmons, M. J. Cook, A. J. Kornberg, and R. M.I. Kapsa Evaluation of Sca-1 and c-Kit As Selective Markers for Muscle Remodelling by Nonhemopoietic Bone Marrow Cells Stem Cells, June 1, 2007; 25(6): 1364 - 1374. [Abstract] [Full Text] [PDF]

				G. A. Challen and M. H. Little A Side Order of Stem Cells: The SP Phenotype. Stem Cells, January 1, 2006; 24(1): 3 - 12. [Abstract] [Full Text] [PDF]

				F. Chretien, P. A. Dreyfus, C. Christov, P. Caramelle, J.-L. Lagrange, B. Chazaud, and R. K. Gherardi In Vivo Fusion of Circulating Fluorescent Cells with Dystrophin-Deficient Myofibers Results in Extensive Sarcoplasmic Fluorescence Expression but Limited Dystrophin Sarcolemmal Expression Am. J. Pathol., June 1, 2005; 166(6): 1741 - 1748. [Abstract] [Full Text] [PDF]

				J. Y. Lee, Z. Qu-Petersen, B. Cao, S. Kimura, R. Jankowski, J. Cummins, A. Usas, C. Gates, P. Robbins, A. Wernig, et al. Clonal Isolation of Muscle-derived Cells Capable of Enhancing Muscle Regeneration and Bone Healing J. Cell Biol., September 5, 2000; 150(5): 1085 - 1100. [Abstract] [Full Text] [PDF]

				J. R. Mendell, J. T. Kissel, A. A. Amato, W. King, L. Signore, T. W. Prior, Z. Sahenk, S. Benson, P. E. McAndrew, R. Rice, et al. Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy N. Engl. J. Med., September 28, 1995; 333(13): 832 - 838. [Abstract] [Full Text] [PDF]

				J. M. Leiden Gene Therapy -- Promise, Pitfalls, and Prognosis N. Engl. J. Med., September 28, 1995; 333(13): 871 - 873. [Full Text]

				E Barr and J. Leiden Systemic delivery of recombinant proteins by genetically modified myoblasts Science, December 6, 1991; 254(5037): 1507 - 1509. [Abstract] [PDF]

				J Dhawan, L. Pan, G. Pavlath, M. Travis, A. Lanctot, and H. Blau Systemic delivery of human growth hormone by injection of genetically engineered myoblasts Science, December 6, 1991; 254(5037): 1509 - 1512. [Abstract] [PDF]